Redhill Biopharma Ltd
RDHL1.070USD
+0.040+3.88%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
3.56MCap. mercado
0.02P/E TTM
Más Datos de Redhill Biopharma Ltd Compañía
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Información de Redhill Biopharma Ltd
Símbolo de cotizaciónRDHL
Nombre de la empresaRedhill Biopharma Ltd
Fecha de salida a bolsaFeb 01, 2011
Director ejecutivoBen-Asher (Dror)
Número de empleados35
Tipo de seguridadDepository Receipt
Fin del año fiscalFeb 01
Dirección21 Ha'arba'a St.
CiudadTEL AVIV-YAFO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIsrael
Código postal6473921
Teléfono97235413131
Sitio Webhttps://www.redhillbio.com/
Símbolo de cotizaciónRDHL
Fecha de salida a bolsaFeb 01, 2011
Director ejecutivoBen-Asher (Dror)
Ejecutivos de Redhill Biopharma Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Eric Swenden
Mr. Eric Swenden
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Gilead Raday
Mr. Gilead Raday
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Guy Goldberg, J.D.
Mr. Guy Goldberg, J.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Rick D. Scruggs
Mr. Rick D. Scruggs
Chief Commercial Officer, Director
Chief Commercial Officer, Director
--
--
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Eric Swenden
Mr. Eric Swenden
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Gilead Raday
Mr. Gilead Raday
Chief Operating Officer
Chief Operating Officer
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: sáb., 3 de ene
Actualizado: sáb., 3 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Gagnon Securities LLC
0.35%
GAMMA Investing LLC
0.09%
Desjardins Securities Inc.
0.07%
Rhumbline Advisers Ltd. Partnership
0.03%
Otro
99.46%
Accionistas
Accionistas
Proporción
Gagnon Securities LLC
0.35%
GAMMA Investing LLC
0.09%
Desjardins Securities Inc.
0.07%
Rhumbline Advisers Ltd. Partnership
0.03%
Otro
99.46%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
0.44%
Research Firm
0.07%
Investment Advisor
0.04%
Otro
99.45%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
36
28.22K
0.55%
-60.13K
2025Q3
38
103.50K
3.11%
-21.59K
2025Q2
39
100.72K
4.39%
-24.30K
2025Q1
45
100.27K
5.67%
-27.27K
2024Q4
61
86.70K
6.77%
-35.73K
2024Q3
77
75.64K
5.91%
-52.57K
2024Q2
82
147.72K
11.56%
-10.64K
2024Q1
84
175.94K
13.78%
+109.25K
2023Q4
94
19.30K
14.67%
-65.78K
2023Q3
106
74.17K
44.30%
+53.53K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Gagnon Securities LLC
17.82K
0.35%
+17.82K
--
Sep 30, 2025
GAMMA Investing LLC
4.83K
0.09%
+4.69K
+3476.30%
Dec 31, 2025
Desjardins Securities Inc.
3.39K
0.07%
--
--
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
1.77K
0.03%
--
--
Sep 30, 2025
BofA Global Research (US)
303.00
0.01%
--
--
Sep 30, 2025
EverSource Wealth Advisors, LLC
38.00
0%
+38.00
--
Sep 30, 2025
The Advocates
19.00
0%
+19.00
--
Sep 30, 2025
Rothschild Investment Corporation
17.00
0%
+17.00
--
Sep 30, 2025
UBS Switzerland AG
16.00
0%
+15.00
+1500.00%
Sep 30, 2025
Group One Trading, L.P.
11.00
0%
--
--
Sep 30, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Aug 06, 2024
Merger
25→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
Mar 17, 2023
Merger
40→1
